Longaeva Partners’s Belite Bio BLTE Stock Holding History

Longaeva Partners’s Portfolio BLTE Stock Details BLTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-33,492	Closed	-$5.34M	–	353
2026 Q1	$5.34M	Buy	+33,492	New	+$5.63M	0.2%	106

Other funds holding BLTE

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Longaeva Partners's BLTE Position: Q2 2026 in Review

Longaeva Partners sold out of Belite Bio (BLTE) in Q2 2026, closing a stake of 33,492 shares — an estimated $5.34M sold.

Longaeva Partners first reported a position in BLTE in Q1 2026 and held it in 1 quarter. The position peaked at $5.34M in Q1 2026. 81 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

Longaeva Partners reported no remaining Belite Bio position as of Q2 2026 after selling out during the quarter.
Longaeva Partners sold 33,492 Belite Bio shares in Q2 2026, an estimated $5.34M.
Longaeva Partners first reported a position in Belite Bio in Q1 2026 and held it in 1 quarter.
Longaeva Partners's Belite Bio position peaked at $5.34M in Q1 2026.
81 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.